tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Diabetes Mellitus, Experimental D003921 85 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Hyperlipidemias D006949 73 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Reperfusion Injury D015427 65 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Morris R Modes of action of FK506, cyclosporin A, and rapamycin. 1994 Transplant. Proc. pmid:7527964
Van Thiel DH et al. Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation. 1990 Transplant. Proc. pmid:1689893
Celli S et al. Long-term survival of heart and liver xenografts with splenectomy and FK 506. 1993 Transplant. Proc. pmid:7679830
Beysens AJ et al. FK 506: monitoring in plasma or in whole blood? 1991 Transplant. Proc. pmid:1721263
Hashikura Y et al. Immunosuppressant switching between cyclosporine and tacrolimus after liver transplantation. 1996 Transplant. Proc. pmid:8623218
Grewal HP et al. Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. 1998 Transplant. Proc. pmid:9636558
Tanabe K et al. Malabsorption of tacrolimus in kidney transplant recipients: a Japanese single center experience. 2000 Transplant. Proc. pmid:11119906
Tian Ch et al. B- and T-lymphocyte attenuator/herpes virus entry mediator as early indicators for acute rejection following kidney transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375291
Yao B et al. The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism. 2013 Jan-Feb Transplant. Proc. pmid:23375298
Miyazaki T et al. Two case reports of successful withdrawal of mycofenolate mofetil after living donor lobar lung transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375323
Vilalta R et al. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation. 2003 Transplant. Proc. pmid:12644102
Ciancio G et al. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. 2003 Transplant. Proc. pmid:12644172
Rath T and Küpper M Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715967
Morell Ginestà M et al. Histology and immunopathology of heart and liver xenografts under low-dose tacrolimus. 2002 Transplant. Proc. pmid:11959305
Schenker P et al. Modified release tacrolimus in de novo immunosuppression after simultaneous pancreas-kidney transplantation--a first single-center experience. 2009 Jul-Aug Transplant. Proc. pmid:19715977
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients treated with tacrolimus. 2002 Transplant. Proc. pmid:11959335
Sigal NH et al. Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? 1991 Transplant. Proc. pmid:1721295
Lipson DA et al. Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. 1998 Transplant. Proc. pmid:9636612
Braun F et al. An ex vivo model to study the intestinal biotransformation of immunosuppressives. 2000 Transplant. Proc. pmid:11120282
Vanrenterghem Y Vascular rejection with tacrolimus and potential long-term graft outcome. 1999 Transplant. Proc. pmid:10576054
Iaria G et al. Prospective study of switch from cyclosporine to tacrolimus for fibroadenomas of the breast in kidney transplantation. 2010 Transplant. Proc. pmid:20534252
Woodle ES A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report. 2005 Transplant. Proc. pmid:15848538
López-Montenegro Soria MA et al. Genetic polymorphisms and individualized tacrolimus dosing. 2010 Transplant. Proc. pmid:20970601
Nowacka-Cieciura E et al. Late conversion to everolimus complicated with necrotizing glomerulonephritis in a renal allograft recipient: case report. 2009 Jan-Feb Transplant. Proc. pmid:19249576
Takada Y et al. Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. 1998 Transplant. Proc. pmid:9838621
Ebbs A et al. Tacrolimus treats ongoing allograft rejection by inhibiting interleukin-10 mediated functional cytotoxic cell infiltration. 2002 Transplant. Proc. pmid:12176404
Savikko J et al. Tacrolimus inhibits platelet-derived growth factor ligand and receptor induction as well as rejection changes in rat renal allografts during long-term follow-up. 2002 Transplant. Proc. pmid:12176405
Okamoto M et al. Detection of allograft rejection in rat small bowel transplantation by analysing the in situ distribution of S-phase lymphocytes. 1994 Transplant. Proc. pmid:7518145
Hisanaga M et al. Successful combination therapy with FK 506 and 15-deoxyspergualin in pancreatic islet xenografting. 1992 Transplant. Proc. pmid:1376513
Barkholt LM et al. New criteria for diagnosing cytomegalovirus hepatitis in liver transplant patients. 1995 Transplant. Proc. pmid:7533375
Ogasa N et al. Successful transplantation of newborn rat intestine as a free graft. 1992 Transplant. Proc. pmid:1376514
Didlake R and Grogan J Effect of FK 506 on rat leukocyte chemotaxis. 1991 Transplant. Proc. pmid:1721327
Hultsch T and Hohman RJ Categorizing receptor-signaling pathways with FK 506 and rapamycin. 1991 Transplant. Proc. pmid:1721328
Nakamura K et al. Renal transplant recipient experiencing pneumatosis cystoides intestinalis: a case report. 2003 Transplant. Proc. pmid:12591410
Akioka K et al. Abdominal pain is a critical complication of mycophenolate mofetil in renal transplant recipients. 2003 Transplant. Proc. pmid:12591411
Takeuchi H et al. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. 2005 Transplant. Proc. pmid:15919452
Hohage H et al. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. 2005 Transplant. Proc. pmid:15919453
Borda B et al. Early histopathological changes in new-onset diabetes after kidney transplantation. Transplant. Proc. pmid:25131129
Ochiai T et al. Phase III study of FK 506 in kidney transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533435
Reis A et al. Mycophenolate mofetil and FK506: two novel immunosuppressants in murine corneal transplantation. 1998 Transplant. Proc. pmid:9865380
Armitage JM et al. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. 1991 Transplant. Proc. pmid:1721359
Armitage JM et al. A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. 1991 Transplant. Proc. pmid:1703336
Emiroglu R et al. Tacrolimus-related neurologic and renal complications in liver transplantation: A single-center experience. 2006 Transplant. Proc. pmid:16549190
Prates LC et al. Pain syndrome induced by calcineurin inhibitor and resolved by conversion to sirolimus in a child after kidney transplantation: a case report. 2012 Transplant. Proc. pmid:23026634
Martin Garcia D et al. Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation "de novo": acute rejection and complications. 2003 Transplant. Proc. pmid:12962761
Naraghi RM et al. Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123013
Nishi K et al. The expression of intestinal CYP3A4 in the piglet model. 2004 Transplant. Proc. pmid:15050159
Nishi K et al. The colon displays an absorptive capacity of tacrolimus. 2004 Transplant. Proc. pmid:15050160
Velio P et al. Rejection and survival after total orthotopic liver-small bowel allotransplantation in pigs immunosuppressed with FK 506. 1996 Transplant. Proc. pmid:8907936
Sonnenday CJ et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. 2002 Transplant. Proc. pmid:12176507
Di Benedetto F et al. University of Modena experience in HIV-positive patients undergoing liver transplantation. 2011 Transplant. Proc. pmid:21620066
Stratta RJ Optimal immunosuppression in pancreas transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083263
Rastellini C et al. Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. 1999 Feb-Mar Transplant. Proc. pmid:10083278
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Tze WJ et al. Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. 1991 Transplant. Proc. pmid:1721391
Morimoto T et al. Blood levels of FK506 after intramuscular and intravenous administration in dogs. 1989 Transplant. Proc. pmid:2468207
Doi R et al. Mechanisms by which FK 506 affects exocrine pancreas in rats. 1991 Transplant. Proc. pmid:1721392
Walgenbach KJ et al. Immunocytes of composite tissue allografts express elevated levels of TGF beta mRNA and protein during chronic rejection. 1997 Feb-Mar Transplant. Proc. pmid:9123418
Millis JM et al. Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123421
Klupp J et al. New approach in drug development: whole blood pharmacodynamic assays reflect biological activities of tacrolimus. 2001 Transplant. Proc. pmid:11377491
Mollison KW et al. Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat. 1996 Transplant. Proc. pmid:8962236
Pozzetto U et al. Effects of immunosuppressive regimens on plasma levels of transforming growth factor-beta 1 in renal transplant recipients. 2002 Transplant. Proc. pmid:12176558
Mao PC et al. Trends in the use of immunosuppressive agents by outpatients after renal transplantation at a medical center in southern Taiwan. 2012 Transplant. Proc. pmid:22310611
Calconi G and Vianello A One-year follow-up of a large European trial comparing dual versus triple tacrolimus-based immunosuppressive regimens following renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267173
Yoshimi F et al. Canine total orthotopic small bowel transplantation under FK 506. 1991 Transplant. Proc. pmid:1721422
Kawauchi M et al. Which are the target vessels of xeno- and allo-lung rejection?--a primate single lung transplantation study. 1996 Transplant. Proc. pmid:8658719
Dresske B et al. Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. 1999 Transplant. Proc. pmid:10331001
Nayeri A et al. Acute Calcineurin Inhibitor Nephrotoxicity Secondary to Turmeric Intake: A Case Report. Transplant. Proc. pmid:28104136
Sicilia-Castro D et al. Reconstruction of a severe facial defect by allotransplantation in neurofibromatosis type 1: a case report. 2011 Transplant. Proc. pmid:21911174
Collier DS et al. FK-506 in experimental renal allografts. 1987 Transplant. Proc. pmid:2445063
Kiberd BA et al. Impact of mycophenolate mofetil loading on drug exposure in the early posttransplant period. 2005 Transplant. Proc. pmid:15964408
Kanatani T et al. Donor leukocytes combine with immunosuppressive drug therapy to prolong limb allograft survival. 2005 Transplant. Proc. pmid:15964421
Lang M et al. Combined liver-kidney transplantation: long-term follow-up in 18 patients. 1998 Transplant. Proc. pmid:9723313
Gnatta D et al. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study. 2010 Transplant. Proc. pmid:20304169
Behr TM et al. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A. 1998 Transplant. Proc. pmid:9723333
Wiederkehr JC et al. Prevalence of posttransplantation lymphoproliferative disease in pediatric liver transplant recipients. 2010 Transplant. Proc. pmid:20304183
Trotter JF Sirolimus in liver transplantation. 2003 Transplant. Proc. pmid:12742496
MacDonald AS Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. 2003 Transplant. Proc. pmid:12742497
Ventura E et al. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring. 2009 Transplant. Proc. pmid:19328963
Ziedina I et al. Reactivation of BK Virus in the Early Period After Kidney Transplantation. 2009 Transplant. Proc. pmid:19328975
Li ZY et al. Analytical performance of the Abbott Architect i2000 tacrolimus assay in Chinese patients after renal transplantation. 2010 Transplant. Proc. pmid:21168731
Ojogho ON et al. Mycophenolate mofetil without antibody induction in pediatric renal transplantation. 2002 Transplant. Proc. pmid:12176641
van der Laan LJ et al. Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. 2010 Transplant. Proc. pmid:21168740
Sindhi R et al. Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. 2002 Transplant. Proc. pmid:12176644
Gruttadauria S et al. A safe immunosuppressive protocol in adult-to-adult living related liver transplantation. 2006 Transplant. Proc. pmid:16757278
Nanmoku K et al. Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus. 2018 Transplant. Proc. pmid:29631750
Takahara S et al. Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients. 1994 Transplant. Proc. pmid:7524219
Llull R et al. Multilineage amplification of graft-vs-host disease-resistant chimerism following rat vascularized bone marrow allotransplantation. 1995 Transplant. Proc. pmid:7544504
Langrehr JM et al. IL-2 receptor antibody induction increases the risk for chronic rejection after liver transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267360
Rao B et al. Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 2016 Transplant. Proc. pmid:27109983
Chang HK et al. Ten-Year Experience With Bowel Transplantation at Seoul St. Mary's Hospital. 2016 Transplant. Proc. pmid:27109981
Fujino Y et al. FK 506 treatment of experimental autoimmune uveoretinitis in primates. 1991 Transplant. Proc. pmid:1721454
González-Pinto I et al. Usefulness of the switch to tacrolimus in liver transplantation. 1999 Transplant. Proc. pmid:10500653
Wang M et al. Acute influence of FK506 on T-lymphocyte populations of peripheral blood and spleen in rats. 2007 Jan-Feb Transplant. Proc. pmid:17275526
Carroll PB et al. Effect of the immunosuppressant FK 506 on insulin release from adult rat islets of Langerhans. 1991 Transplant. Proc. pmid:1703688
Morris-Stiff G et al. Preoperative induction with tacrolimus does not have a detrimental effect on primary graft function in adult cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636499
Sakr MF et al. Protective effect of FK 506 against hepatic ischemia in rats. 1991 Transplant. Proc. pmid:1703689
Eghtesad B et al. Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics. 1998 Transplant. Proc. pmid:9636500
Scholler G et al. Comparison of cyclosporine A and FK506 with regard to complaints and psychosocial characteristics before and after liver transplantation. 1997 Transplant. Proc. pmid:9270822
Pichlmayr R et al. Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. 1997 Transplant. Proc. pmid:9270825